Acalabrutinib for untreated and treated chronic lymphocytic leukaemia – Appraisal Consultation Document
In DRAFT guidance, NICE recommend acalabrutinib for untreated chronic lymphocytic leukaemia in adults, only if they have a 17p deletion or TP53 mutation, and for those who have had 1 previous treatment, only if ibrutinib is their only suitable treatment option.
Source:
National Institute for Health and Care Excellence